• Abstract

    Brain metastases are a frequent consequence of “non-small cell lung cancer (NSCLC)”, one of the most prevalent cancers with a poor prognosis. For the best possible patient outcomes, detecting and treating NSCLC brain metastases involve substantial hurdles and calls for a multidisciplinary approach. This article intends to provide an overview of current methods for diagnosing and treating NSCLC brain metastases. It examines the various available treatment options, diagnostic techniques, and their effects on patient outcomes. A thorough literature review was done to find pertinent studies, clinical suggestions, and professional advice about the specialized management of NSCLC. The chosen articles were examined to learn about molecular screening techniques, individualized treatment plans, and diagnostic procedures. For individualized treatment, precise NSCLC identification and prognosis are essential. Techniques such as imaging and endoscopy are used to collect tissue samples. It is advised to do a molecular screening for oncogenic changes. Evaluation of PD-L1 expression informs therapy decisions. The molecular profile determines the first line of treatment, followed by chemotherapy and immunotherapy, and cancer tissue samples help to detect resistance mechanisms. For the best possible patient results, NSCLC therapy must be personalized and incorporate precise pathology evaluation, molecular assessment, and precision therapeutic approaches. To progress in precision medicine in lung cancer treatment, further research is required to find novel molecular markers, especially those that predict the effectiveness of immunotherapy.

  • References

    1. Alduais, Y., Zhang, H., Fan, F., Chen, J. and Chen, B.(2023). Non-small cell lung cancer (NSCLC): A review of risk factors, diagnosis, and treatment. Medicine, 102(8):e32899-e32899.10.1097/MD.0000000000032899
    2. Arrieta, O., Ramírez‐Tirado, L.A., Caballé‐Perez, E., Mejia‐Perez, A., Zatarain‐Barrón, Z.L., Cardona, A.F., Lozano‐Ruíz, F., Segura‐González, M., Cruz‐Rico, G., Maldonado, F. and Rosell, R. (2020). The response rate of patients with baseline brain metastases from recently diagnosed non‐small cell lung cancer receiving radiotherapy according to EGFR, ALK, and KRAS mutation status. Thoracic cancer, 11(4), pp.1026-1037.10.1111/1759-7714.13359
    3. Bianconi, F., Palumbo, I., Spanu, A., Nuvoli, S., Fravolini, M. L., & Palumbo, B. (2020). PET/CT radiomics in lung cancer: an overview. applied sciences, 10(5), 1718. 10.3390/app10051718
    4. Churilla, T.M. and Weiss, S.E. (2019). Emerging trends in the management of brain metastases from non-small cell lung cancer. Current Oncology Reports, 20, pp.1-9.10.1007/s11912-018-0695-9
    5. Conde, E., Rojo, F., Gómez, J., Enguita, A. B., Abdulkader, I., González, A., ... & de Álava, E. (2022). Molecular diagnosis in non-small-cell lung cancer: expert opinion on ALK and ROS1 testing. Journal of Clinical Pathology, 75(3), 145-153. 10.1136/jclinpath-2021-207490
    6. Cui, W., Franchini, F., Alexander, M., Officer, A., Wong, H.L., IJzerman, M., Desai, J. and Solomon, B.J. (2020). Real-world outcomes in KRAS G12C mutation-positive non-small cell lung cancer. Lung Cancer, 146, pp.310-317.10.1016/j.lungcan.2020.06.030
    7. D’Angelo, A., Sobhani, N., Chapman, R., Bagby, S., Bortoletti, C., Traversini, M., Ferrari, K., Voltolini, L., Darlow, J. and Roviello, G. (2020). Focus on ROS1-positive non-small cell lung cancer (NSCLC): crizotinib, resistance mechanisms and the newer generation of targeted therapies—cancers, 12(11), p.3293.10.3390/cancers12113293
    8. Dohopolski, M. and Iyengar, P. (2021). Oligometastatic non-small cell lung cancer: a narrative review of stereotactic ablative radiotherapy. Ann Palliat Med, 10(5), pp.5944-5953.10.1016/j.prro.2023.04.004
    9. Dohopolski, M. and Iyengar, P. (2021). Oligometastaticnon-small cell lung cancer: a narrative review of stereotactic ablative radiotherapy. Ann Palliat Med, 10(5), pp.5944-5953.10.1016/j.prro.2023.04.004
    10. Duma, N., Santana-Davila, R. and Molina, J.R. (2019), August. Non–small cell lung cancer: epidemiology, screening, diagnosis, and treatment. In Mayo Clinic Proceedings (Vol. 94, No. 8, pp. 1623-1640). Elsevier.10.1016/j.mayocp.2019.01.01
    11. Dumoulin, D.W., Bironzo, P., Passiglia, F., Scagliotti, G.V. and Aerts, J.G. (2023). Rare thoracic cancers: a comprehensive overview of diagnosing and managing small cell lung cancer, malignant pleural mesothelioma, and thymic epithelial tumors. European Respiratory Review, 32(167).10.1183/16000617.0174-2022
    12. Esposito Abate, R., Frezzetti, D., Maiello, M.R., Gallo, M., Camerlingo, R., De Luca, A., De Cecio, R., Morabito, A. and Normanno, N. (2020). Next generation sequencing-based profiling of cell-free DNA in patients with advanced non-small cell lung cancer: advantages and pitfalls. Cancers, 12(12), p.3804.10.3390/cancers12123804
    13. Gobbini, E., Swalduz, A., GiajLevra, M., Ortiz-Cuaran, S., Toffart, A.C., Pérol, M., Moro-Sibilot, D. and Saintigny, P. (2020). Implementing ctDNA analysis in the clinic: challenges and opportunities in non-small cell lung cancer. Cancers, 12(11), p.3112.10.3390/cancers12113112
    14. Harrison, P.T., Vyse, S. and Huang, P.H., 2020, April. Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer. In Seminars in cancer biology (Vol. 61, pp. 167-179). Academic Press.10.1186/s12943-020-01260-z
    15. Horvath, L., & Pircher, A. (2021). ASCO 2020 non-small lung cancer (NSCLC) personal highlights. memo-Magazine of European Medical Oncology, 14(1), 66-69.1007/s12254-020-00673-2
    16. Horvath, L., & Pircher, A. (2021). ASCO 2020 non-small lung cancer (NSCLC) personal highlights. memo-Magazine of European Medical Oncology, 14(1), 66-69.101007/s12254-020-00673-2
    17. Horvath, L., Thienpont, B., Zhao, L., Wolf, D. and Pircher, A., 2020. Overcoming immunotherapy resistance in non-small cell lung cancer (NSCLC)-novel approaches and future outlook. Molecular Cancer, 19, pp.1-15.
    18. Kim, M., Suh, C.H., Lee, S.M., Kim, H.C., Aizer, A.A., Yanagihara, T.K., Bai, H.X., Guenette, J.P., Huang, R.Y. and Kim, H.S. (2020). Diagnostic yield of staging brain MRI in patients with newly diagnosed non–small cell lung cancer. Radiology, 297(2), pp.419-427.10.1148/radiol.2020201194
    19. Majeed, U., Manochakian, R., Zhao, Y. and Lou, Y. (2021). Targeted therapy in advanced non-small cell lung cancer: current advances and future trends. Journal of Hematology & Oncology, 14(1), pp.1-20.10.1186/s13045-021-01121-2
    20. Pacheco, J. M., Camidge, D. R., Doebele, R. C., & Schenk, E. (2019). A changing of the guard: immune checkpoint inhibitors with and without chemotherapy as first line treatment for metastatic non-small cell lung cancer. Frontiers in oncology, 9, 195. 10.3389/fonc.2019.00195
    21. Page, S., Milner-Watts, C., Perna, M., Janzic, U., Vidal, N., Kaudeer, N., Ahmed, M., McDonald, F., Locke, I., Minchom, A. and Bhosle, J. (2020). Systemic treatment of brain metastases in non-small cell lung cancer. European Journal of Cancer, 132, pp.187-198.10.1016/j.ejca.2020.03.006
    22. Papadaki, M.A., Sotiriou, A.I., Vasilopoulou, C., Filika, M., Aggouraki, D., Tsoulfas, P.G., Apostolopoulou, C.A., Rounis, K., Mavroudis, D. and Agelaki, S. (2020). Optimization of the enrichment of circulating tumor cells for downstream phenotypic analysis in patients with non-small cell lung cancer treated with anti-PD-1 immunotherapy. Cancers, 12(6), p.1556.10.3390/cancers12061556
    23. Perrotta, F., Nankivell, M., Adizie, J.B., Maqsood, U., Elshafi, M., Jafri, S., Lerner, A.D., Woolhouse, I., Munavvar, M., Evison, M. and Booton, R. 2020. Endobronchial ultrasound-guided transbronchial needle aspiration for PD-L1 testing in non-small cell lung cancer. Chest, 158(3), pp.1230-1239.10.1016/j.chest.2020.04.059
    24. Petrova, M.P., Eneva, M.I., Arabadjiev, J.I., Conev, N.V., Dimitrova, E.G., Koynov, K.D., Karanikolova, T.S., Valev, S.S., Gencheva, R.B., Zhbantov, G.A. and Ivanova, A.I.(2020). Neutrophil to lymphocyte ratio is a potential predictive marker for treatment with pembrolizumab as a second-line treatment in non-small cell lung cancer patients. Bioscience trends, 14(1), pp.48-55.10.5582/bst.2019.01279Mantovani, C., Gastino, A., Cerrato, M., Badellino, S., Ricardi, U. and Levis, M.(2021). Modern radiation therapy for managing brain metastases from non-small cell lung cancer: current approaches and future directions. Frontiers in Oncology, p.4587. 10.3390/cancers13092141
    25. Rodenak-Kladniew, B., Gambaro, R., Cisneros, J. S., Huck-Iriart, C., Padula, G., Castro, G. R., ... & Islan, G. A. (2023). Enhanced anticancer activity of encapsulated geraniol into biocompatible lipid nanoparticles against A549 human lung cancer cells. Journal of Drug Delivery Science and Technology, 80, 104159.10.1016/j.jddst.2023.104159
    26. Schegoleva, A.A., Khozyainova, A.A., Fedorov, A.A., Gerashchenko, T.S., Rodionov, E.O., Topolnitsky, E.B., Shefer, N.A., Pankova, O.V., Durova, A.A., Zavyalova, M.V. and Perelmuter, V.M.(2021). Prognosis of non-small cell lung cancer progression types: current state and perspectives. Cell PhysiolBiochem, 55(S2), pp.29-48.doi: 10.33594/000000340.
    27. Steindl, A., Yadavalli, S., Gruber, K.A., Seiwald, M., Gatterbauer, B., Dieckmann, K., Frischer, J.M., Klikovits, T., Zöchbauer‐Müller, S., Grisold, A. and Hoda, M.A.R. (2020). Neurological symptom burden impacts survival prognosis in patients with newly diagnosed non–small cell lung cancer brain metastases. Cancer, 126(19), pp.4341-4352.10.1002/cncr.33085
    28. Tan, A. C. (2022). The role of liquid biopsy in the diagnostic testing algorithm for advanced lung cancer. Onco, 2(3), 181-185. 10.3390/onco2030012
    29. Wang, S., Jia, M., He, Z., & Liu, X. S. (2018). APOBEC3B and APOBEC mutational signature as potential predictive markers for immunotherapy response in non-small cell lung cancer. Oncogene, 37(29), 3924-3936. 10.1038/s41388-018-0245-9
    30. Witlox, W.J., Ramaekers, B.L., Lacas, B., Le Pechoux, C., Pignon, J.P., Sun, A., Wang, S.Y., Hu, C., Redman, M., van derNoort, V. and Li, N.(2021). Individual patient data meta-analysis of prophylactic cranial irradiation in locally advanced non-small cell lung cancer. Radiotherapy and Oncology, 158, pp.40-47.10.1016/j.compeleceng.2022.108528
    31. Ye, L., Leslie, C., Jacques, A., Ardakani, N. M., Amanuel, B., & Millward, M. (2019). Programmed death ligand-1 expression in non-small cell lung cancer in a Western Australian population and correlation with clinicopathologic features. Modern Pathology, 32(4), 524-531. 10.1038/s41379-018-0173-9
    32. Zimmermann, S., Dziadziuszko, R. and Peters, S. (2019). Indications and limitations of chemotherapy and targeted agents in non-small cell lung cancer brain metastases. Cancer treatment reviews, 40(6), pp.716-722.10.1016/j.ctrv.2014.03.005

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Copyright (c) 2023 Malque Publishing

How to cite

Jamuna, J., Eugene, T., Prusty, P. K., Kamar, S., Basu, K., & Ravindran, S. (2024). Current approaches in the diagnosis and management of non-small cell lung cancer brain metastases. Multidisciplinary Reviews, 6, e2023ss016. https://doi.org/10.31893/multirev.2023ss016
  • Article viewed - 165
  • PDF downloaded - 75